

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Claim 1-9. (Cancelled)

Claim 10. (Presently Amended) A method of treating a subject suffering from the adverse physiological effects of the presence of lipoarabinomannan in circulation, ~~the said~~ method comprising administering ~~to the subject~~ to the subject a pharmaceutical composition comprising a BPI protein product selected from the group consisting of amino-terminal fragments of BPI holoprotein having a molecular weight of 21-25 kD by SDS-PAGE and dimeric forms thereof, rBPI<sub>21</sub>, rBPI<sub>23</sub>, rBPI and BPI-derived peptides, or fusion protein comprising said BPI protein product, and a pharmaceutically acceptable diluent, adjuvant, or carrier.

Claim 11. (Original) The method of claim 10 wherein the adverse physiological effects comprise compromised immune response to microbes or tumor cells due to lipoarabinomannan-induced inhibition of macrophage activation by T-cell lymphokines.

Claim 12. (Original) The method of claim 10 wherein the adverse physiological effects comprise increased production of a cytokine by the subject.

Claim 13. (Original) The method of claim 10 wherein the composition is administered orally.

Claim 14. (Original) The method of claim 10 wherein the composition is administered intravenously.

Claim 15. (Original) The method of claim 10 wherein the composition is administered as an aerosol.

Claim 16. (Original) The method of claim 10 wherein the BPI protein product is a 21-25 kD amino-terminal fragment of Bactericidal/permeability-increasing protein.

Application No. 10/658,112

Preliminary Amendment dated February 10, 2005

Claim 17. (Original) The method of claim 10, wherein the composition further comprises a surfactant.

Claim 18-23 (Cancelled).